作者: Gang Hu , Qin Liu , Jian-ying Ma , Cheng-yuan Liu
DOI: 10.1155/2018/7375169
关键词:
摘要: Introduction. Pretreatment platelet-to-lymphocyte ratio (PLR) has been considered a prognostic factor in various cancers. However, the application of PLR assessment patients with cholangiocarcinoma remains controversial. This study aimed to evaluate value pretreatment cholangiocarcinoma. Methods. A systematic search was performed MEDLINE, EMBASE, and Cochrane Library identify studies assessing significance Three databases were searched from inception August 5, 2018. The primary outcome overall survival (OS), secondary outcomes recurrence-free (RFS) progression-free (PFS). Pooled hazard ratios (HRs) or odds (ORs) 95% confidence intervals (CIs) calculated using random-effects models. Results. total 9 including 2395 finally enrolled meta-analysis based on inclusion exclusion criteria. All included retrospective observational cohorts. Elevated predicted poor OS (HR: 1.38, CI: 1.19-1.62, P < 0.001) RFS PFS (HR = 1.55; CI 1.27-1.88; 0.001). Moreover, elevated highly associated male sex (male versus female OR 0.59, 0.44-0.80, R1 resection margin (OR 2.09, 1.24-3.54, 0.006). Conclusion. present demonstrated that might serve as useful biomarker